

Objectives

Limited information is available on cost associated with AHSCT and in particular those detailing the cost of pre-transplant chemotherapy and post-transplant follow-up care in DLBCL. The aim of this study was to estimate the average hospital cost per patient for AHSCT, including pre-AHSCT chemotherapy cost and the 6-month transplant follow-up care cost in DLBCL.

Methods

A retrospective study of patients with RR (Relapsed/Refractory) DLBCL (Diffuse Large B-Cell Lymphoma) at ages 18 and more was performed from French hospital database (PMSI) 2013 to 2016. Hospital stays were selected with the ICD10 code CIM C833 "Diffuse large B-cell lymphoma" in position of: Principal Diagnosis (PD) or Related Diagnosis (RD) or Associated Diagnosis between 01/01/2013 and 01/01/2014. Refractory patients could not be identified in the database. Relapsed patients were defined as patients by 2 criteria:

- (a) at least one complete cycle of rituximab chemotherapy
- (b) bone marrow biopsy followed by hospitalization.

For each allograft identified with CCAM (Classification Commune des Actes Médicaux) procedure FEFFL009 "intravenous injection of a cell therapy for transplant", a cost evaluation per patient (€2017) was calculated according to the French health service perspective by detailing: the cost of pre-transplant chemotherapy (chemotherapy stays between the biopsy procedure determining relapse and transplantation), cost of transplant and the cost of follow-up in DLBCL (up to 6 month after the end of the transplantation procedure).

Conclusions


The study showed that the economic burden of AHSCT in relapsed DLBCL patients based on the hospital cost is significant. The total cost of R DLBCL patients in 2017 is €15.7 million from the French National Insurance perspective. The mean allogenic transplant cost per patient is **€93,233 ±14,973**.

DISCUSSIONS


A cost sensitive analysis was performed to DLBCL patients without RR definition. The burden of DLBCL was fewer (€14.5 million) as well as the mean allogenic transplant cost per patient: **€76,179 ±24,774**.

Direct cost of Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT) for Relapsed/Refractory (RR) **Diffuse Large B-Cell Lymphoma (DLBCL) patients** from the French hospital perspective

Patient chart Flow




Relapsed DLBCL with a AHSCT patients characteristics (6 patients)




AHSCT Protocol cost split

Allogenic Transplant cost per patient in Euros (€)


The pre AHSCT chemotherapy cost



Patient Transplant Cost




The follow-up cost up to 6 month after the transplantation procedure




Length of stay in days

The pre AHSCT chemotherapy cost



Patient Transplant Cost



The follow-up cost up to 6 month after the transplantation procedure

